Showing results (151-160 of 253) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II TrialMartin Hutchings, Anna Sureda, Francesc Bosch, et al.British Journal of Haematology|June 15, 2024
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE studyAngelica Barone, Annalisa Chiappella, Beatrice Casadei, et al.The Lancet. Haematology|June 12, 2026
Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective studyFabio Efficace, Pier Luigi Zinzani, Francesca Bonifazi, et al.Blood|March 7, 2015
Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantationAlessandra Roberto, Luca Castagna, Veronica Zanon, et al.The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphomaCorrado Tarella, Roberto Passera, Michele Magni, et al.Haematologica|July 22, 2021
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcomeAnna Dodero, Anna Guidetti, Fabrizio Marino, et al.Blood|March 14, 2013
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 studyGösta Gahrton, Simona Iacobelli, Bo Björkstrand, et al.Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.Pageof 26